The U.S. intravenous solutions market size is anticipated to reach USD 7.91 billion by 2030 and is projected to grow at a CAGR of 7.8% during the forecast period. The market is experiencing growth due to the increasing prevalence of disease and a rise in surgical procedures. The aging population, which is more prone to non-communicable diseases such as cancer, neurological, cardiovascular disorders, and spinal injuries, is also driving market expansion. In October 2024, Fresenius Medical Care announced initiatives to mitigate disruptions in dialysis care. The company is enhancing the production of PD and IV solutions by leveraging its global production facilities. Prompted by the Department of Health & Human Services, Fresenius Medical Care is committed to meeting the demand for IV fluids and peritoneal dialysis (PD) products through improved production strategies.
IV hydration therapy effectively treats severe dehydration, especially in people with chronic conditions like diabetes or kidney diseases, by replenishing the body's electrolyte balance. The primary treatment is saline solution, water mixed with sodium chloride. Solutions with sugars like glucose, dextrose, or levulose are also standard. In December 2023, Baxter, a prominent company in infusion therapies and technologies, finished the first stage of its IV bag recycling trial in partnership with Northwestern Medicine. This program has successfully diverted over six tons of PVC IV bag material from being disposed of in landfills. If these bags were placed end to end, they would stretch across Chicago, demonstrating the project's contribution to environmental preservation.
IV hydration therapy effectively treats severe dehydration, especially in people with chronic conditions like diabetes or kidney diseases, by replenishing the body's electrolyte balance. The primary treatment is saline solution, water mixed with sodium chloride. Solutions with sugars like glucose, dextrose, or levulose are also standard. In December 2023, Baxter, a prominent company in infusion therapies and technologies, finished the first stage of its IV bag recycling trial in partnership with Northwestern Medicine. This program has successfully diverted over six tons of PVC IV bag material from being disposed of in landfills. If these bags were placed end to end, they would stretch across Chicago, demonstrating the project's contribution to environmental preservation.
U.S. Intravenous Solutions Market Report Highlights
- The total parenteral nutrition (TPN) type segment held the largest revenue share of 67.14% in 2024 due to its critical role in providing essential nutrients directly into the bloodstream for patients who cannot consume food orally or absorb nutrients through their gastrointestinal tract.
- Based on nutrients, the single-dose amino acid solution segment dominated the segment with a market share of 31.33% in 2024 as it offers a convenient and effective means of delivering protein directly to patients. These solutions are tailored to specific patient needs, ensuring that they receive adequate amino acids necessary for recovery and maintenance of bodily functions.
- The vitamins & minerals segment is expected to grow at the fastest CAGR over the forecast period. These micronutrients are essential for various metabolic processes and overall health, particularly in patients receiving TPN or other forms of parenteral nutrition.
- In terms of end use, the hospitals segment dominated the segment with a market share of 46.0% in 2024 due to their critical role in acute care settings. Hospitals require a steady supply of intravenous solutions for various medical procedures, including surgeries and emergency care, making them essential players in this market.
- The home segment is expected to grow at the fastest CAGR over the forecast period due to an increasing preference for at-home treatments, which are more convenient and cost-effective for patients.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments
- Competitive Landscape: Explore the market presence of key players worldwide
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
The leading players in the U.S. Intravenous Solutions market include:
- Fresenius Kabi AG
- Pfizer Inc.
- Baxter
- JW Life Science
- ICU Medical, Inc.
- Grifols USA, LLC
- B. Braun Medical Inc
- Amphastar Pharmaceuticals, Inc.
- Athenex, Inc.
- Rockwell Medical, Inc.
- Exela Pharma Sciences, LLC
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Intravenous Solutions Market Variables, Trends & Scope
Chapter 4. U.S. Intravenous Solutions Market: Product Estimates & Trend Analysis
Chapter 5. U.S. Intravenous Solutions Market: Nutrients Estimates & Trend Analysis
Chapter 6. U.S. Intravenous Solutions Market: End Use Estimates & Trend Analysis
Chapter 7. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Fresenius Kabi AG
- Pfizer Inc.
- Baxter
- JW Life Science
- ICU Medical, Inc.
- Grifols USA, LLC
- B. Braun Medical Inc
- Amphastar Pharmaceuticals, Inc.
- Athenex, Inc.
- Rockwell Medical, Inc.
- Exela Pharma Sciences, LLC
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 105 |
| Published | October 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 5.03 Billion |
| Forecasted Market Value ( USD | $ 7.91 Billion |
| Compound Annual Growth Rate | 7.8% |
| Regions Covered | United States |
| No. of Companies Mentioned | 11 |
